The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Guidelines for depot antipsychotic treatment in schizophrenia
Open accessAbstract
These guidelines for depot antipsychotic treatment in schizophrenia were developed during a two-day consensus conference held on July 29 and 30, 1995 in Siena, Italy. Depot antipsychotic medications were developed in the 1960s as an attempt to improve the long-term treatment of schizophrenia (and potentially other disorders benefiting from long-term antipsychotic medication). Depot drugs as distinguishable from shorter acting intramuscularly administered agents can provide a therapeutic concentration of at least a seven day duration in one parenteral dose. The prevention of relapse in schizophrenia remains an enormous public health challenge worldwide and improvements in this area can have tremendous impact on morbidity, mortality and quality of life, as well as direct and indirect health care costs. Though there has been debate as to what extent depot (long-acting injectable) antipsychotics are associated with significantly fewer relapses and rehospitalizations, in our view when all of the data from individual trials and metaanalyses are taken together, the findings are extremely compelling in favor of depot drugs. However in many countries throughout the world fewer than 20% of individuals with schizophrenia receive these medications. The major advantage of depot antipsychotics over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among patients with schizophrenia and is a frequent cause of relapse. In terms of adverse effects, there are not convincing data that depot drugs are associated with a significantly higher incidence of adverse effects than oral drugs. Therefore in our opinion any patient for whom long-term antipsychotic treatment is indicated should be considered for depot drugs. In choosing which drug the clinician should consider previous experience, personal patient preference, patients history of response (both therapeutic and adverse effects) and pharmacokinetic properties. In conclusion the use of depot antipsychotics has important advantages in facilitating relapse prevention. Certainly pharmacotherapy must be combined with other treatment modalities as needed, but the consistent administration of the former is often what enables the latter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive Textbook of Psychiatry
Freedman, A. M., & Kaplan, H. I. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196712000-00052 · Cited by 3,799
Influence of Family Life on the Course of Schizophrenic Disorders: A Replication
Brown, G. W., Birley, J. L. T., & Wing, J. K. (1972) · British Journal of Psychiatry · doi:10.1192/bjp.121.3.241 · Cited by 1,770
Hogan, T. P., Awad, A. G., & Eastwood, R. (1983) · Psychological Medicine · doi:10.1017/s0033291700050182 · Cited by 1,028
CONDITIONS PREDISPOSING TO SUICIDE: A REVIEW
MILES, C. P. (1977) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197704000-00002 · Cited by 504
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.7.801 · Cited by 455
Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 435
The Effects of Clozapine on Tardive Dyskinesia
Lieberman, J. A., Saltz, B. L., Johns, C. A., Pollack, S., Borenstein, M., & Kane, J. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.503 · Cited by 302
Self-citationDepot Antipsychotic Drugs: Place in Therapy
Davis, J. M., Metalon, L., Watanabe, M. D., & Blake, L. (1994) · Drugs · doi:10.2165/00003495-199447050-00004 · Cited by 295
Rating of Medication Influences (ROMI) Scale in Schizophrenia
Weiden, P., Rapkin, B., Mott, T., Zygmunt, A., Goldman, D., Horvitz-Lennon, M., & Frances, A. (1994) · Schizophrenia Bulletin · doi:10.1093/schbul/20.2.297 · Cited by 274
Kane, J. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790070083010 · Cited by 273
Self-citation
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Kane, J. M., Eerdekens, M., Lindenmayer, J.-P., Keith, S. J., Lesem, M., & Karcher, K. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1125 · Cited by 489
Self-citationThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
Adams, C. E., Fenton, M. K. P., Quraishi, S., & David, A. S. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.4.290 · Cited by 288
(2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7090su1cj · Cited by 282
Metadata
- Authors
- Kane, J. M., Aguglia, E., Altamura, A. C., Gutierrez, J. L. A., Brunello, N., Fleischhacker, W. W., Gaebel, W., Gerlach, J., Guelfi, J.-D., Kissling, W., Lapierre, Y. D., Lindström, E., Mendlewicz, J., Racagni, G., Carulla, L. S., & Schooler, N. R.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 1998-02
- Volume
- 8
- Issue
- 1
- Pages
- 55-66
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2153190128
- Cited by
- 332
- References
- 57
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guidelines for depot antipsychotic treatment in schizophrenia. https://app.cochat.ai/papers/10.1016/s0924-977x(97)00045-x
- The paper
- Kane, J. M., Aguglia, E., Altamura, A. C., Gutierrez, J. L. A., Brunello, N., Fleischhacker, W. W., Gaebel, W., Gerlach, J., Guelfi, J.-D., Kissling, W., Lapierre, Y. D., Lindström, E., Mendlewicz, J., Racagni, G., Carulla, L. S., & Schooler, N. R. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology. https://doi.org/10.1016/s0924-977x(97)00045-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.